AZN has been the topic of several other reports. Societe Generale restated a buy rating and set a GBX 7,000 ($86.63) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 14th. Morgan Stanley raised their price objective on AstraZeneca plc from GBX 5,000 ($61.88) to GBX 5,800 ($71.78) and gave the stock an overweight rating in a research note on Friday, August 19th. Deutsche Bank AG restated a buy rating and set a GBX 5,800 ($71.78) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.50) price objective on AstraZeneca plc and gave the stock a sell rating in a research note on Tuesday, September 6th. Finally, Jefferies Group restated a buy rating and set a GBX 5,800 ($71.78) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 21st. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Hold and a consensus target price of GBX 4,960.13 ($61.39).
Shares of AstraZeneca plc (LON:AZN) opened at 4950.50 on Monday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The firm’s 50 day moving average is GBX 4,998.32 and its 200 day moving average is GBX 4,469.91. The stock’s market capitalization is GBX 62.62 billion.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.